3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
82
Phase 1/2
44
Phase 2
37
Phase 3
9
Phase NA
3
Phase EARLY_PHASE1
3
Phase 4
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
6
Head and Neck Neoplasms
6
Lung Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Skin Neoplasms
2
Recurrence
2
Cholangiocarcinoma
2
Advanced Solid Tumor
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous NSCLC
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Mouth Neoplasms
1
Mesothelioma
1
Liver Neoplasms
1
Laryngeal Neoplasms
1
Laryngeal Diseases
1
Klatskin Tumor
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
pembrolizumab
×
Clear all
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled